Plasma and CSF NfL and progranulin levels are sensitive indicators of axonal injury but lack disease specificity, with similar elevations occurring in ALS and many other neurodegenerative conditions; hence, there is no ‘gold standard’ biomarker available [44,45]. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.